AHCO — Adapthealth Income Statement
0.000.00%
- $1.35bn
- $3.04bn
- $3.24bn
Annual income statement for Adapthealth, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,455 | 2,971 | 3,200 | 3,261 | 3,245 |
| Cost of Revenue | |||||
| Gross Profit | 515 | 501 | 570 | 775 | 705 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2,249 | 2,791 | 3,828 | 3,003 | 3,154 |
| Operating Profit | 205 | 179 | -628 | 258 | 90.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 191 | 97.9 | -724 | 136 | -15.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 158 | 73.1 | -675 | 94.8 | -66 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 156 | 69.3 | -679 | 90.4 | -70.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 142 | 63.4 | -679 | 82.7 | -70.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.5 | 0.652 | -0.767 | 0.868 | 0.034 |